<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434353</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-464-4437</org_study_id>
    <nct_id>NCT03434353</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Antiviral Activity of Inarigivir Soproxil (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spring Bank Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety and tolerability of the 12
      week treatment regimens of inarigivir soproxil (GS-9992) plus tenofovir alafenamide (TAF) or
      commercially available nucleoside/nucleotide (NUC) in adults with chronic hepatitis B (CHB),
      to evaluate the antiviral activity of 12 weeks of inarigivir soproxil plus TAF versus TAF
      alone in viremic CHB participants (Groups 1-3, 5), and to evaluate the antiviral activity of
      12 weeks of inarigivir soproxil with commercially available NUC(s) in virally suppressed CHB
      participants (Group 4).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Groups 1-5: Proportion of Participants With ≥ 0.5 log10 IU/mL Decline in Hepatitis B Surface Antigen (HBsAg) from Baseline at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Groups 1-5: Proportion of Participants With ≥ 1 log10 IU/mL Decline in Hepatitis B Surface Antigen (HBsAg) from Baseline at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Groups 1-5: Proportion of HBeAg-Positive Participants who Achieve Hepatitis B e Antigen (HBeAg) Loss</measure>
    <time_frame>Baseline through Week 48</time_frame>
    <description>HBeAg loss is defined as HBeAg changing from positive at baseline to negative at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Groups 1-5: Proportion of HBeAg-Positive Participants who Achieve HBeAg Seroconversion</measure>
    <time_frame>Baseline through Week 48</time_frame>
    <description>HBeAg seroconversion is defined as HBeAg loss and HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Groups 1-5: Proportion of Participants who Achieve HBsAg Loss</measure>
    <time_frame>Baseline through Week 48</time_frame>
    <description>HBsAg loss is defined as HBsAg changing from positive at baseline to negative at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Groups 1-3 and 5: Proportion of Participants with Drug Resistance Mutations</measure>
    <time_frame>Baseline through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Groups 1-3 and 5: Change from Baseline in Hepatitis B Virus (HBV) DNA</measure>
    <time_frame>Baseline through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Groups 1-5: Change from Baseline in Quantitative HBsAg</measure>
    <time_frame>Baseline through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Group 4: Proportion of Participants Experiencing HBV Virologic Breakthrough during 12 Weeks of Inarigivir Soproxil Treatment</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Virologic breakthrough is defined as having two consecutive visits of HBV deoxyribonucleic acid (DNA) ≥ 69 IU/mL.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group 1 (Inarigivir Soproxil 50 mg + TAF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inarigivir Soproxil 50 mg (2 x 25 mg capsule) plus TAF for 12 weeks, followed by TAF for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (TAF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAF for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (Inarigivir Soproxil 200 mg + TAF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inarigivir Soproxil 200 mg (2 x 100 mg tablet) plus TAF for 12 weeks, followed by TAF for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (Inarigivir Soproxil 100 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inarigivir Soproxil 100 mg tablet for 12 weeks in virally suppressed participants currently being treated with a commercially available NUC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 (Inarigivir Soproxil 200 mg + TAF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inarigivir Soproxil 400 mg (2 x 200 mg tablet) plus TAF for 12 weeks, followed by TAF for 36 weeks (Group 5 applies to Hong Kong only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inarigivir Soproxil</intervention_name>
    <description>Administered orally once daily one hour before or one hour after a meal</description>
    <arm_group_label>Group 1 (Inarigivir Soproxil 50 mg + TAF)</arm_group_label>
    <arm_group_label>Group 3 (Inarigivir Soproxil 200 mg + TAF)</arm_group_label>
    <arm_group_label>Group 4 (Inarigivir Soproxil 100 mg)</arm_group_label>
    <arm_group_label>Group 5 (Inarigivir Soproxil 200 mg + TAF)</arm_group_label>
    <other_name>SB 9200</other_name>
    <other_name>GS-9992</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAF</intervention_name>
    <description>25 mg tablet administered orally once daily with food</description>
    <arm_group_label>Group 1 (Inarigivir Soproxil 50 mg + TAF)</arm_group_label>
    <arm_group_label>Group 2 (TAF)</arm_group_label>
    <arm_group_label>Group 3 (Inarigivir Soproxil 200 mg + TAF)</arm_group_label>
    <arm_group_label>Group 5 (Inarigivir Soproxil 200 mg + TAF)</arm_group_label>
    <other_name>GS-7340</other_name>
    <other_name>Vemlidy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  All Groups:

               -  Aged 18 to 70 years of age, inclusive, based on the date of screening visit.

               -  Chronic hepatitis B infection

          -  Groups 1-3 and 5:

               -  Individuals not taking any prescribed HBV NUC treatment

          -  Group 4:

               -  HBV DNA ≤ 20 IU/mL at Screening by Central Lab.

               -  Have been on a commercially available HBV NUC treatment(s)

        Key Exclusion Criteria:

          -  Co-infection with HCV, HIV, or HDV.

          -  Extensive bridging fibrosis or cirrhosis

          -  Evidence of hepatocellular carcinoma on imaging

          -  Any history of, or current evidence of, clinical hepatic decompensation (e.g.,
             ascites, encephalopathy or variceal hemorrhage).

          -  Chronic liver disease of a non-HBV etiology

          -  Current alcohol or substance abuse

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alice Ho Miu Ling Nethersole Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital-HK</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Ilsan</city>
        <zip>10380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea, Seoul Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

